Prenetics Global Limited (PRE)
| Market Cap | 282.21M +317.2% |
| Revenue (ttm) | 92.39M +479.8% |
| Net Income | -37.71M |
| EPS | -2.68 |
| Shares Out | 16.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 192,284 |
| Open | 16.06 |
| Previous Close | 15.92 |
| Day's Range | 15.63 - 16.77 |
| 52-Week Range | 5.58 - 23.63 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 31.25 (+86.35%) |
| Earnings Date | May 14, 2026 |
About PRE
Prenetics Global Limited, a health sciences company, focuses on consumer health in Hong Kong and the United States. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide insights into health, wellness, and genetic predispositions. Prenetics Global Limited was founded in 2014 a... [Read more]
Financial Performance
In 2025, Prenetics Global's revenue was $92.39 million, an increase of 479.76% compared to the previous year's $15.94 million. Losses were -$37.71 million, -18.56% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PRE stock is "Strong Buy." The 12-month stock price target is $31.25, which is an increase of 86.35% from the latest price.
News
MEXC SPACEX(PRE) Launchpad Subscriptions Surpass $56 million, with the Offering Oversubscribed by Up to 15.5x
MEXC SPACEX(PRE) Launchpad is with total subscriptions surpassing $56 million and the most competitive pool reaching an oversubscription rate of 15.5x.
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
Multi-year partnership lands as Prenetics' IM8 raises full-year 2026 revenue guidance to $190 million to $210 million following nearly 6x year-over-year growth in Q1 2026 Shetty is IM8's first global ...
Prenetics Global Q1 Earnings Call Highlights
Prenetics Global NASDAQ: PRE said its first-quarter results reflected the company's shift away from diagnostics and genome testing toward a subscription-driven consumer health model anchored by its IM...
Prenetics Global Earnings Call Transcript: Q1 2026
Q1 2026 revenue surged 334% year-over-year to $36M, driven by IM8's rapid growth and expanding margins. Guidance for 2026 IM8 revenue was raised to $190M-$210M, with new product launches and channel diversification representing further upside.
Prenetics Global Earnings release: Q1 2026
Prenetics Global released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Prenetics Global Slides: Q1 2026
Prenetics Global has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion
Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M
Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million , up 23.1% from IM8 revenue of $27.4 million in Q4 2025 Raises full-year 2026 IM8 revenue guidance to $190 million...
Prenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with Davi...
Prenetics' IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
NEW YORK and MIAMI, May 07, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded...
Prenetics files to sell 2.36M Class A ordinary shares for holders
09:26 EDT Prenetics (PRE) files to sell 2.36M Class A ordinary shares for holders
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
Prenetics’ IM8 enters partnership with Superpower
Prenetics (PRE) Global announced a strategic partnership with Superpower. The partnership connects clinical-grade supplementation with comprehensive blood diagnostics, enabling an optimized testing lo...
Prenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and ...
Prenetics Global Transcript: The 38th Annual Roth Conference
Panelists from leading wellness and consumer brands discussed the importance of authentic influencer partnerships, emphasizing that genuine product use, equity alignment, and scientific validation drive long-term success. Data-driven tracking, multi-year deals, and a mix of macro and micro-influencers were highlighted as best practices.
Prenetics Global Transcript: The 38th Annual Roth Conference
IM8 has rapidly scaled to $100 million ARR in under a year by focusing on a unique all-in-one supplement, leveraging celebrity ambassadors, and a robust direct-to-consumer model. Strong retention, global reach, and aggressive digital marketing—powered by AI—support ambitious growth targets and new product launches in 2026.
Prenetics Global Transcript: Sidoti March Small-Cap Virtual Conference
IM8 drove explosive growth, reaching $120 million ARR in its first year and fueling a strategic focus on global DTC expansion. With robust liquidity, premium products, and strong ambassador partnerships, the brand projects $180–$200 million revenue in 2026 and aims for profitability by Q4 2027.
Prenetics initiated with a Buy at Lake Street
Lake Street initiated coverage of Prenetics (PRE) with a Buy rating and $29 price target Having divested three non-core assets, ACT Genomics, Europa, and its remaining stake in Insighta, Prenetics…
Prenetics authorizes $40M share repurchase program
Prenetics (PRE) Global announced that its Board of Directors has authorized a share repurchase program of up to $40,000,000 over a 12-month period. Danny Yeung, CEO of Prenetics, commented: “We…
Prenetics announces executive open market share purchases
Prenetics (PRE) Global announced that members of its executive leadership team have executed a second round of open market purchases of Prenetics common stock during the week of February 23…
Prenetics announces launch of Daily Ultimate Essentials PRO
Prenetics (PRE) Global announced the launch of Daily Ultimate Essentials PRO. Alongside the reformulated product, Prenetics is also introducing two new flavours – Mango + Passionfruit and Lemon + Oran...
Prenetics Global Earnings Call Transcript: Q4 2025
Record 2025 revenue of $92.4M, up 480% year-over-year, driven by IM8's explosive growth and global expansion. Strategic divestitures strengthened liquidity to $171M with no debt. 2026 guidance targets $180M-$200M IM8 revenue and 60% gross margin, with profitability expected by Q4 2027.
Prenetics Global Earnings release: Q4 2025
Prenetics Global released its Q4 2025 earnings on February 18, 2026, summarizing the period's financial results.
Prenetics Global Slides: Q4 2025
Prenetics Global has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 18, 2026.
Prenetics Global Annual report: Q4 2025
Prenetics Global has published its Q4 2025 annual report on February 18, 2026.